Urovant Sciences Ltd (NASDAQ:UROV) major shareholder Sciences Ltd. Roivant bought 21,122 shares of the stock in a transaction on Thursday, June 6th. The shares were acquired at an average cost of $7.86 per share, for a total transaction of $166,018.92. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Sciences Ltd. Roivant also recently made the following trade(s):
- On Wednesday, May 29th, Sciences Ltd. Roivant bought 14,485 shares of Urovant Sciences stock. The shares were acquired at an average cost of $7.63 per share, for a total transaction of $110,520.55.
Shares of UROV stock opened at $7.91 on Friday. The firm’s 50-day moving average price is $7.81. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.34 and a current ratio of 8.34. The firm has a market cap of $235.36 million and a PE ratio of -1.79. Urovant Sciences Ltd has a twelve month low of $4.05 and a twelve month high of $14.49.
Several brokerages have issued reports on UROV. SunTrust Banks began coverage on shares of Urovant Sciences in a research note on Friday, March 15th. They set a “buy” rating and a $24.00 target price on the stock. HC Wainwright began coverage on shares of Urovant Sciences in a research note on Monday, March 11th. They set a “buy” rating and a $28.00 target price on the stock. Zacks Investment Research raised shares of Urovant Sciences from a “hold” rating to a “buy” rating and set a $9.75 target price on the stock in a research note on Thursday, April 18th. Finally, JPMorgan Chase & Co. set a $24.00 price target on shares of Urovant Sciences and gave the company a “buy” rating in a research report on Friday, June 14th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. Urovant Sciences currently has an average rating of “Buy” and a consensus target price of $21.63.
A number of hedge funds and other institutional investors have recently bought and sold shares of UROV. Barclays PLC purchased a new stake in shares of Urovant Sciences during the fourth quarter worth approximately $37,000. Marshall Wace North America L.P. purchased a new stake in shares of Urovant Sciences during the first quarter worth approximately $49,000. Two Sigma Investments LP purchased a new stake in shares of Urovant Sciences during the fourth quarter worth approximately $72,000. Weiss Multi Strategy Advisers LLC increased its stake in shares of Urovant Sciences by 38.2% during the fourth quarter. Weiss Multi Strategy Advisers LLC now owns 15,000 shares of the company’s stock worth $99,000 after buying an additional 4,146 shares during the period. Finally, Marshall Wace LLP purchased a new position in Urovant Sciences in the first quarter valued at approximately $325,000. 21.92% of the stock is currently owned by institutional investors.
Urovant Sciences Company Profile
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
See Also: What is a Candlestick Chart?
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.